- 21Apr, 2026
This article was originally published on drugdiscoveryonline.com. By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals For decades, sexually transmitted infections (STIs), such as gonorrhea and chlamydia, were viewed as straightforward to treat. A single injection or short oral course of antibiotics was typically sufficient. [...]
Confronting Antibiotic-Resistant STIs: Advancing Next-Generation DHFR Inhibitors for Dual-Pathogen Coverage
For decades, infections like gonorrhea and chlamydia were treated as routine; a quick course of antibiotics and life went on. Now, that comfort is collapsing. Neisseria gonorrhoeae has steadily outmaneuvered drug after drug, such as macrolides, fluoroquinolones and more;1 and today we rely on a [...]
Antibiotic-Resistant Gonorrhea Emerges as a Growing Men’s Health Crisis During STI Awareness Month
Author(s) Contagion Editorial Team TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI. April is sexually transmitted infection (STI) Awareness Month, and with it brings [...]
World Health Day: How Antimicrobial Resistance Is Changing Medicine — A Layered Defense Approach
World Health Day is a good moment to call attention to a silent emergency that’s putting the health of everyone on our planet at risk: Antimicrobial resistance (AMR) is quietly eroding the foundations of modern medicine. On a day when we talk about equity and [...]
- 12Feb, 2026
February 10, 2026 — TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of Directors. TAXIS Pharmaceuticals, a clinical-stage company focused on developing investigational therapies to combat multidrug-resistant bacterial infections and address antimicrobial resistance [...]
- 2Feb, 2026
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point. While US government prioritisation of AMR will likely remain low in 2026, the EU and Australia are ramping up incentives and R&D funding. [...]
- 21Jan, 2026
A conversation with Ajit Parhi, Ph.D., chief scientific officer, TAXIS Pharmaceuticals Antimicrobial resistance (AMR) poses a grave threat to global public health and is estimated to cause around 10 million deaths each year by 2050if not addressed. While U.S. government prioritization of AMR is likely [...]
